Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
9.59
-0.47 (-4.67%)
At close: Aug 28, 2026, 4:00 PM EDT
9.37
-0.22 (-2.29%)
Pre-market: Aug 31, 2026, 4:40 AM EDT

Capricor Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--22.2725.182.550.24
Revenue Growth
---11.55%886.81%941.85%-21.06%
Gross Profit
-99.73-84.45-27.7-11.27-19.27-13.33
Operating Income
-135.16-108.14-42.56-24.08-29.7-20.94
Net Income
-129.42-105.04-40.47-22.29-29.02-20.02
Earnings Per Share
-2.47-2.26-1.15-0.83-1.18-0.87
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
237.93318.13151.5239.4941.4234.89
Total Debt
91.0514.521.452.242.562.87
Net Cash (Debt)
146.89303.61150.0637.2538.8632.01
Net Cash Growth
20.64%102.32%302.84%-4.14%21.38%-1.03%
Net Cash Per Share
2.806.534.261.391.581.39

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-104-69.81-40-25.64.92-16.81
Capital Expenditures
-25.78-11.72-1.54-2.05-3.36-1.2
Free Cash Flow
-129.78-81.54-41.53-27.641.56-18.01
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---124.37%-44.76%--
Operating Margin
---191.12%-95.63%-1163.93%-8549.86%
Pretax Margin
---181.70%-88.52%-1137.37%-8175.86%
Profit Margin
---181.71%-88.52%-1137.37%-8175.86%
FCF Margin
---186.50%-109.79%61.02%-7352.29%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-195.91----
P/FCF Ratio
----62.58-
PS Ratio
--28.185.9838.19288.92